DMS Imaging Past Earnings Performance
Past criteria checks 0/6
DMS Imaging has been growing earnings at an average annual rate of 45.3%, while the Biotechs industry saw earnings growing at 15.7% annually. Revenues have been growing at an average rate of 75.7% per year.
Key information
45.3%
Earnings growth rate
62.6%
EPS growth rate
| Biotechs Industry Growth | -3.6% |
| Revenue growth rate | 75.7% |
| Return on equity | -8.3% |
| Net Margin | -2.2% |
| Last Earnings Update | 30 Jun 2023 |
Revenue & Expenses Breakdown
How DMS Imaging makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 40 | -1 | 12 | 0 |
| 31 Mar 23 | 38 | -3 | 12 | 0 |
| 31 Dec 22 | 37 | -6 | 12 | 0 |
| 30 Sep 22 | 66 | -7 | 19 | 0 |
| 30 Jun 22 | 19 | 0 | 6 | 0 |
| 31 Mar 22 | 9 | 2 | 3 | 0 |
| 31 Dec 21 | 38 | 0 | 11 | 0 |
| 30 Sep 21 | 0 | 2 | 1 | 0 |
| 30 Jun 21 | 0 | 0 | 1 | 0 |
| 31 Mar 21 | 0 | -1 | 1 | 0 |
| 31 Dec 20 | 0 | -1 | 1 | 0 |
| 30 Sep 20 | 0 | -5 | 2 | 4 |
| 30 Jun 20 | 0 | -9 | 2 | 7 |
| 31 Mar 20 | 1 | -12 | 3 | 10 |
| 31 Dec 19 | 1 | -16 | 4 | 14 |
| 30 Sep 19 | 1 | -16 | 3 | 13 |
| 30 Jun 19 | 1 | -17 | 3 | 13 |
| 31 Mar 19 | 1 | -16 | 3 | 12 |
| 31 Dec 18 | 1 | -14 | 3 | 10 |
| 30 Sep 18 | 1 | -12 | 3 | 10 |
| 30 Jun 18 | 1 | -11 | 3 | 9 |
| 31 Mar 18 | 1 | -11 | 2 | 10 |
| 31 Dec 17 | 1 | -12 | 2 | 11 |
| 30 Sep 17 | 1 | -12 | 2 | 11 |
| 30 Jun 17 | 2 | -12 | 2 | 12 |
| 31 Mar 17 | 2 | -12 | 2 | 12 |
| 31 Dec 16 | 2 | -12 | 2 | 12 |
| 30 Sep 16 | 1 | -12 | 2 | 11 |
| 30 Jun 16 | 0 | -12 | 1 | 11 |
| 31 Mar 16 | 0 | -10 | 1 | 9 |
| 31 Dec 15 | 0 | -8 | 1 | 7 |
| 31 Dec 14 | 0 | -4 | 1 | 3 |
| 31 Dec 13 | 0 | -2 | 1 | 2 |
Quality Earnings: ALIMG is currently unprofitable.
Growing Profit Margin: ALIMG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALIMG is unprofitable, but has reduced losses over the past 5 years at a rate of 45.3% per year.
Accelerating Growth: Unable to compare ALIMG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALIMG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: ALIMG has a negative Return on Equity (-8.31%), as it is currently unprofitable.